PI3Kdelta Inhibitors
2 drugsAbout PI3Kdelta
PI3K-delta is an intracellular signaling enzyme involved in cell growth, proliferation, survival, and immune cell function. It phosphorylates phosphatidylinositol lipids, initiating downstream signaling cascades that regulate these processes. As a member of the PI3K family, it plays a crucial role in various cellular activities.
Currently, there is no genetic evidence directly linking PI3K-delta to specific diseases. However, its involvement in fundamental cellular processes makes it a valuable target for therapeutic intervention, particularly in oncology and other immune-related disorders.
PI3K-delta is targeted by two FDA-approved small molecule drugs: COPIKTRA (SECURA) and JOENJA (PHARMING). COPIKTRA is used in oncology, while JOENJA is used in other therapeutic areas, highlighting the target's potential across different indications.
Top PI3Kdelta Drugs
The competitive landscape consists of two companies, SECURA and PHARMING, with approved drugs targeting PI3K-delta.
Low market concentration suggests relatively low barriers to entry for new companies targeting PI3K-delta.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline